Skip to content

Trial · Interventional

RecruitingPhase 2Registry data

BPC 157 for Acute Hamstring Muscle Strain Repair

Short name BPC-HAMSTR

Overview

Status
Recruiting
Phase
Phase 2
Enrollment
120 participants (estimated)
Sponsor
Hudson Biotech · Industry
Design
Randomized · Quadruple masking
Countries
1 country

China

Start
2 Feb 2026
Primary completion
14 Feb 2027 (estimated)
Completion
17 Feb 2028 (estimated)
First posted
27 Feb 2026
Last update posted
27 Feb 2026
Conditions
Hamstring Muscle Strain · Skeletal Muscle Injury

Timeline

1 trial · 1 ongoing

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
2026202720282029
  1. Ph 2

    BPC-HAMSTR

    NCT07437547

    2 Feb 2026 to est. 17 Feb 2028

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Interventions

  • Pentadecapeptide BPC 157Drug
  • PlaceboDrug

Arms2

  • Experimental

    Arm 1: Experimental - BPC 157

    Participants receive investigational pentadecapeptide BPC 157 plus standardized rehabilitation.

  • Experimental

    Arm 2: Placebo Comparator - Placebo

    Participants receive matching placebo plus standardized rehabilitation.

Primary outcomes2

Outcomes the sponsor listed as primary.

  1. Time to return to unrestricted sport participation (days)

    Time frame · 8 Weeks

    Registry description

    defined as clearance by a blinded sports medicine clinician and completion of a standardized functional performance battery without pain-limited stopping.

  2. Change from baseline to Day 14 in MRI-assessed hamstring injury volume (cm^3), measured by blinded central radiology review.

    Time frame · 14 Days

Secondary outcomes(3)
  1. Change in pain during activity on a 0-10 Numeric Rating Scale (NRS; 0 = no pain, 10 = worst pain).

    Time frame · 56 Days

  2. Hamstring strength limb symmetry index (LSI) by isokinetic dynamometry

    Time frame · 56 Days

  3. Change in Lower Extremity Functional Scale (LEFS; 0-80, higher scores indicate better function)

    Time frame · 56 Days

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies0

Studies that cite this trial.

No study cites this trial.

Eligibility

Who could join, as posted.

Sex
All
Age
from 18 Years up to 45 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Age 18 to 45 years. * Acute posterior thigh pain consistent with hamstring strain with onset within 72 hours prior to screening. * MRI-confirmed grade II hamstring strain of the biceps femoris, semitendinosus, or semimembranosus, with measurable lesion. * Pre-injury physical activity \>= 3 sessions/week or participation in organized recreational sport. * Willingness to follow the standardized rehabilitation protocol and attend all study visits. * For participants of childbearing potential: negative pregnancy test at baseline and agreement to use effective contraception during dosing and for 30 days after last dose. Exclusion Criteria: * Grade III hamstring tear, tendon avulsion, or injury requiring surgical management. * Concomitant lower extremity injury that would interfere with rehabilitation or outcome assessment. * Prior hamstring strain on the index limb within the past 6 months. * Use of systemic corticosteroids, anabolic agents, platelet-rich plasma, stem-cell products, or investigational peptides/growth factors within 30 days prior to screening. * Known bleeding disorder or current therapeutic anticoagulation. * Significant uncontrolled medical illness (e.g., severe cardiovascular, hepatic, or renal disease) that increases study risk. * Known allergy or hypersensitivity to components of the investigational product or placebo. * Pregnant or breastfeeding. * Current participation in another interventional clinical study or participation within 30 days prior to screening. * Currently subject to a formal anti-doping testing program (e.g., WADA/USADA-aligned) where use of an investigational peptide could create a regulatory conflict, unless explicitly approved by the relevant authority

PepBank is a research reference. Talk to a doctor before you use any peptide.